John L. Wallace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John L. Wallace has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Linda Vong
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
4 shared publicationsEnnio Ongini
NicOx Research Institute, Milan, Italy
2 shared publicationsManlio Bolla
NicOx Research Institute, Milan, Italy
2 shared publicationsStephanie Syer
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
2 shared publicationsWebb McKnight
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
2 shared publicationsElena Verdu
Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada
1 shared publication
Latest Publications
- Open Access
- 1 July 2012
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 17 (1) , 58-67
Hydrogen Sulfide: An Endogenous Mediator of Resolution of Inflammation and Injury
Significance: Hydrogen sulfide is emerging as an important mediator of many aspects of inflammation, and perhaps most importantly as a factor promoting the resolution of inflammation and repair of injury. Recent Advances: In the gastrointestinal tract, H 2 S has been shown to promote healing of ulcers and the resolution of mucosal inflammation. On the other hand, suppression of endogenous H 2 S synthesis impairs mucosal defense and leads to increased granulocyte infiltration. H 2 S has been exploited in the design of more effective and safe anti-inflammatory drugs. Critical Issues: Enteric bacteria can be a significant source of H 2 S, which could affect mucosal integrity; indeed, luminal H 2 S can serve as an alternative to oxygen as a metabolic substrate for mitochondrial respiration in epithelial cells. Enterocytes and colonocytes thereby represent a “metabolic barrier” to the diffusion of bacteria-derived H 2 S into the subepithelial space. A compromise of this barrier could result in modulation of mucosal function and integrity by bacterial H 2 S. Future Directions: Improvements in methods for measurement of H 2 S and development of more selective inhibitors are crucial for gaining a better understanding of the pathophysiological importance of this mediator. Results from animal studies suggest that H 2 S-releasing agents are promising therapeutic agents for many indications, but these compounds need to be assessed in a clinical setting. Antioxid. Redox Signal. 17, 58–67.
- 1 July 2012
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 17 (1) , 58-67
Open AccessHydrogen Sulfide: An Endogenous Mediator of Resolution of Inflammation and Injury
Significance: Hydrogen sulfide is emerging as an important mediator of many aspects of inflammation, and perhaps most importantly as a factor promoting the resolution of inflammation and repair of injury. Recent Advances: In the gastrointestinal tract, H 2 S has been shown to promote healing of ulcers and the resolution of mucosal inflammation. On the other hand, suppression of endogenous H 2 S synthesis impairs mucosal defense and leads to increased granulocyte infiltration. H 2 S has been exploited in the design of more effective and safe anti-inflammatory drugs. Critical Issues: Enteric bacteria can be a significant source of H 2 S, which could affect mucosal integrity; indeed, luminal H 2 S can serve as an alternative to oxygen as a metabolic substrate for mitochondrial respiration in epithelial cells. Enterocytes and colonocytes thereby represent a “metabolic barrier” to the diffusion of bacteria-derived H 2 S into the subepithelial space. A compromise of this barrier could result in modulation of mucosal function and integrity by bacterial H 2 S. Future Directions: Improvements in methods for measurement of H 2 S and development of more selective inhibitors are crucial for gaining a better understanding of the pathophysiological importance of this mediator. Results from animal studies suggest that H 2 S-releasing agents are promising therapeutic agents for many indications, but these compounds need to be assessed in a clinical setting. Antioxid. Redox Signal. 17, 58–67.
- Open Access
- 9 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35196
Gastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence
Nonsteroidal anti-inflammatory drugs are among the most commonly used prescription and over-the-counter medications, but they often produce significant gastrointestinal ulceration and bleeding, particularly in elderly patients and patients with certain co-morbidities. Novel anti-inflammatory drugs are seldom tested in animal models that mimic the high risk human users, leading to an underestimate of the true toxicity of the drugs. In the present study we examined the effects of two novel NSAIDs and two commonly used NSAIDs in models in which mucosal defence was expected to be impaired. Naproxen, celecoxib, ATB-346 (a hydrogen sulfide- and naproxen-releasing compound) and NCX 429 (a nitric oxide- and naproxen-releasing compound) were evaluated in healthy, arthritic, obese, and hypertensive rats and in rats of advanced age (19 months) and rats co-administered low-dose aspirin and/or omeprazole. In all models except hypertension, greater gastric and/or intestinal damage was observed when naproxen was administered in these models than in healthy rats. Celecoxib-induced damage was significantly increased when co-administered with low-dose aspirin and/or omeprazole. In contrast, ATB-346 and NCX 429, when tested at doses that were as effective as naproxen and celecoxib in reducing inflammation and inhibiting cyclooxygenase activity, did not produce significant gastric or intestinal damage in any of the models. These results demonstrate that animal models of human co-morbidities display the same increased susceptibility to NSAID-induced gastrointestinal damage as observed in humans. Moreover, two novel NSAIDs that release mediators of mucosal defence (hydrogen sulfide and nitric oxide) do not induce significant gastrointestinal damage in these models of impaired mucosal defence.
- 9 April 2012
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (4) , e35196
Open AccessGastrointestinal-Sparing Effects of Novel NSAIDs in Rats with Compromised Mucosal Defence
Nonsteroidal anti-inflammatory drugs are among the most commonly used prescription and over-the-counter medications, but they often produce significant gastrointestinal ulceration and bleeding, particularly in elderly patients and patients with certain co-morbidities. Novel anti-inflammatory drugs are seldom tested in animal models that mimic the high risk human users, leading to an underestimate of the true toxicity of the drugs. In the present study we examined the effects of two novel NSAIDs and two commonly used NSAIDs in models in which mucosal defence was expected to be impaired. Naproxen, celecoxib, ATB-346 (a hydrogen sulfide- and naproxen-releasing compound) and NCX 429 (a nitric oxide- and naproxen-releasing compound) were evaluated in healthy, arthritic, obese, and hypertensive rats and in rats of advanced age (19 months) and rats co-administered low-dose aspirin and/or omeprazole. In all models except hypertension, greater gastric and/or intestinal damage was observed when naproxen was administered in these models than in healthy rats. Celecoxib-induced damage was significantly increased when co-administered with low-dose aspirin and/or omeprazole. In contrast, ATB-346 and NCX 429, when tested at doses that were as effective as naproxen and celecoxib in reducing inflammation and inhibiting cyclooxygenase activity, did not produce significant gastric or intestinal damage in any of the models. These results demonstrate that animal models of human co-morbidities display the same increased susceptibility to NSAID-induced gastrointestinal damage as observed in humans. Moreover, two novel NSAIDs that release mediators of mucosal defence (hydrogen sulfide and nitric oxide) do not induce significant gastrointestinal damage in these models of impaired mucosal defence.
- 17 March 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (6) , 1432-1434
Hydrogen Sulfide: A Rescue Molecule for Mucosal Defence and Repair
- 17 March 2012
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 57 (6) , 1432-1434
Hydrogen Sulfide: A Rescue Molecule for Mucosal Defence and Repair
- 6 December 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (1) , 67-74
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies
The mechanisms underlying the ability of nonsteroidal anti‐inflammatory drugs (NSAIDs) to cause ulceration in the stomach and proximal duodenum are well understood, and this injury can largely be prevented through suppression of gastric acid secretion (mainly with proton pump inhibitors). In contrast, the pathogenesis of small intestinal injury induced by NSAIDs is less well understood, involving more complex mechanisms than those in the stomach and proximal duodenum. There is clear evidence for important contributions to NSAID enteropathy of enteric bacteria, bile and enterohepatic recirculation of the NSAID. There is no evidence that suppression of gastric acid secretion will reduce the incidence or severity of NSAID enteropathy. Indeed, clinical data suggest little, if any, benefit. Animal studies suggest a significant exacerbation of NSAID enteropathy when proton pump inhibitors are co‐administered with the NSAID. This worsening of damage appears to be linked to changes in the number and types of bacteria in the small intestine during proton pump inhibitor therapy. The distinct mechanisms of NSAID‐induced injury in the stomach/proximal duodenum versus the more distal small intestine likely dictate distinct strategies for prevention.
- 6 December 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (1) , 67-74
NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategies
The mechanisms underlying the ability of nonsteroidal anti‐inflammatory drugs (NSAIDs) to cause ulceration in the stomach and proximal duodenum are well understood, and this injury can largely be prevented through suppression of gastric acid secretion (mainly with proton pump inhibitors). In contrast, the pathogenesis of small intestinal injury induced by NSAIDs is less well understood, involving more complex mechanisms than those in the stomach and proximal duodenum. There is clear evidence for important contributions to NSAID enteropathy of enteric bacteria, bile and enterohepatic recirculation of the NSAID. There is no evidence that suppression of gastric acid secretion will reduce the incidence or severity of NSAID enteropathy. Indeed, clinical data suggest little, if any, benefit. Animal studies suggest a significant exacerbation of NSAID enteropathy when proton pump inhibitors are co‐administered with the NSAID. This worsening of damage appears to be linked to changes in the number and types of bacteria in the small intestine during proton pump inhibitor therapy. The distinct mechanisms of NSAID‐induced injury in the stomach/proximal duodenum versus the more distal small intestine likely dictate distinct strategies for prevention.
- Top Cited PapersOpen Access
- 1 October 2011
- Published by Elsevier in Gastroenterology
- Vol. 141 (4) , 1314-1322.e5
Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis
- 1 October 2011
- Published by Elsevier in Gastroenterology
- Vol. 141 (4) , 1314-1322.e5
Top Cited PapersOpen AccessProton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis
- 1 March 2011
- Published by Elsevier in The American Journal of Pathology
- Vol. 178 (3) , 1126-1133
Muc-2–Deficient Mice Display a Sex-Specific, COX-2–Related Impairment of Gastric Mucosal Repair
- 1 March 2011
- Published by Elsevier in The American Journal of Pathology
- Vol. 178 (3) , 1126-1133
Muc-2–Deficient Mice Display a Sex-Specific, COX-2–Related Impairment of Gastric Mucosal Repair
- Open Access
- 14 June 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (26) , 12023-12027
A pro-resolution mediator, prostaglandin D 2 , is specifically up-regulated in individuals in long-term remission from ulcerative colitis
Patients with ulcerative colitis (UC) experience unpredictable bouts of active inflammation and ulceration. Relatively little attention has been paid to the role of antiinflammatory mediators in the pathogenesis of UC, although rodent studies suggest an important role of prostaglandin (PG) D 2 in the resolution of tissue injury and inflammation. The present study was performed to determine if colonic PGD 2 synthesis was altered in patients in remission from UC and if expression of the key enzymes and receptors related to PGD 2 was altered. During routine colon-cancer screening, colonic biopsies were obtained from healthy individuals, some of whom had been in remission from UC, without treatment, for >4 y. UC patients with active disease or in medically induced remission were also biopsied. Only patients with active UC exhibited elevated expression of several proinflammatory cytokines (TNFα and IFNγ) and colonic PGE 2 synthesis. In contrast, colonic PGD 2 synthesis was only elevated (∼3-fold) in the healthy individuals with a prior history of UC. This group also exhibited significantly elevated expression of DP1, the key receptor mediating the antiinflammatory actions of PGD 2 . Expression of the synthetic enzymes cyclooxygenase-1, cyclooxygenase-2, and hematopoietic PGD synthase was not altered in the healthy individuals with a prior history of UC. These results show a marked up-regulation of synthesis of an antiinflammatory prostanoid and expression of its receptor, specifically in individuals in long-term remission from UC. This is consistent with animal studies showing the importance of PGD 2 in the induction and maintenance of remission from colitis.
- 14 June 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (26) , 12023-12027
Open AccessA pro-resolution mediator, prostaglandin D 2 , is specifically up-regulated in individuals in long-term remission from ulcerative colitis
Patients with ulcerative colitis (UC) experience unpredictable bouts of active inflammation and ulceration. Relatively little attention has been paid to the role of antiinflammatory mediators in the pathogenesis of UC, although rodent studies suggest an important role of prostaglandin (PG) D 2 in the resolution of tissue injury and inflammation. The present study was performed to determine if colonic PGD 2 synthesis was altered in patients in remission from UC and if expression of the key enzymes and receptors related to PGD 2 was altered. During routine colon-cancer screening, colonic biopsies were obtained from healthy individuals, some of whom had been in remission from UC, without treatment, for >4 y. UC patients with active disease or in medically induced remission were also biopsied. Only patients with active UC exhibited elevated expression of several proinflammatory cytokines (TNFα and IFNγ) and colonic PGE 2 synthesis. In contrast, colonic PGD 2 synthesis was only elevated (∼3-fold) in the healthy individuals with a prior history of UC. This group also exhibited significantly elevated expression of DP1, the key receptor mediating the antiinflammatory actions of PGD 2 . Expression of the synthetic enzymes cyclooxygenase-1, cyclooxygenase-2, and hematopoietic PGD synthase was not altered in the healthy individuals with a prior history of UC. These results show a marked up-regulation of synthesis of an antiinflammatory prostanoid and expression of its receptor, specifically in individuals in long-term remission from UC. This is consistent with animal studies showing the importance of PGD 2 in the induction and maintenance of remission from colitis.
- Open Access
- 1 May 2010
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 12 (9) , 1125-1133
Physiological and Pathophysiological Roles of Hydrogen Sulfide in the Gastrointestinal Tract
Like nitric oxide and carbon monoxide, hydrogen sulfide has historically been recognized as an industrial pollutant, but in recent years, it has been shown to be an important mediator of many physiological processes. Hydrogen sulfide contributes to the maintenance of gastrointestinal mucosal defense and repair. It also exerts many antiinflammatory effects, including inhibition of leukocyte adherence to the vascular endothelium and leukocyte migration to sites of inflammation. Conversely, inhibition of endogenous hydrogen sulfide synthesis leads to a loss of mucosal integrity and to an increase in mucosal inflammation. Hydrogen sulfide therefore appears to have overlapping actions with nitric oxide and prostaglandins in terms of modulating mucosal defense and resolution of inflammation. Recent evidence suggests that these properties of hydrogen sulfide can be exploited in the design of novel therapies for ulcerative and inflammatory diseases of the gastrointestinal tract. Antioxid. Redox Signal. 12, 0000–0000.
- 1 May 2010
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 12 (9) , 1125-1133
Open AccessPhysiological and Pathophysiological Roles of Hydrogen Sulfide in the Gastrointestinal Tract
Like nitric oxide and carbon monoxide, hydrogen sulfide has historically been recognized as an industrial pollutant, but in recent years, it has been shown to be an important mediator of many physiological processes. Hydrogen sulfide contributes to the maintenance of gastrointestinal mucosal defense and repair. It also exerts many antiinflammatory effects, including inhibition of leukocyte adherence to the vascular endothelium and leukocyte migration to sites of inflammation. Conversely, inhibition of endogenous hydrogen sulfide synthesis leads to a loss of mucosal integrity and to an increase in mucosal inflammation. Hydrogen sulfide therefore appears to have overlapping actions with nitric oxide and prostaglandins in terms of modulating mucosal defense and resolution of inflammation. Recent evidence suggests that these properties of hydrogen sulfide can be exploited in the design of novel therapies for ulcerative and inflammatory diseases of the gastrointestinal tract. Antioxid. Redox Signal. 12, 0000–0000.
- Open Access
- 12 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (6) , 1236-1246
Markedly reduced toxicity of a hydrogen sulphide‐releasing derivative of naproxen (ATB‐346)
Background and purpose: Hydrogen sulphide is an important mediator of gastric mucosal defence. The use of non‐steroidal anti‐inflammatory drugs continues to be limited by their toxicity, particularly in the upper gastrointestinal tract. We evaluated the gastrointestinal safety and anti‐inflammatory efficacy of a novel hydrogen sulphide‐releasing derivative of naproxen, ATB‐346 [2‐(6‐methoxy‐napthalen‐2‐yl)‐propionic acid 4‐thiocarbamoyl‐phenyl ester].Experimental approach: The ability of ATB‐346 versus naproxen to cause gastric damage was evaluated in healthy rats and in rats with compromised gastric mucosal defence. Effects on the small intestine and on the healing of ulcers were also assessed. The ability of ATB‐346 to inhibit cyclooxygenase‐1 and 2 and to reduce inflammation in vivo was also evaluated.Key results: ATB‐346 suppressed gastric prostaglandin E2 synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine. In situations in which the gastric mucosa was rendered significantly more susceptible to naproxen‐induced damage (e.g. ablation of sensory afferent nerves, inhibition of endogenous nitric oxide or hydrogen sulphide synthesis, co‐administration with aspirin, antagonism of KIR6.x channels), ATB‐346 did not cause significant damage. Unlike naproxen and celecoxib, ATB‐346 accelerated healing of pre‐existing gastric ulcers. In a mouse airpouch model, ATB‐346 suppressed cyclooxygenase‐2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB‐346 was as effective as naproxen in adjuvant‐induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB‐346 did not elevate blood pressure in hypertensive rats.Conclusions and implications: ATB‐346 exhibits anti‐inflammatory properties similar to naproxen, but with substantially reduced gastrointestinal toxicity.
- 12 March 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 159 (6) , 1236-1246
Open AccessMarkedly reduced toxicity of a hydrogen sulphide‐releasing derivative of naproxen (ATB‐346)
Background and purpose: Hydrogen sulphide is an important mediator of gastric mucosal defence. The use of non‐steroidal anti‐inflammatory drugs continues to be limited by their toxicity, particularly in the upper gastrointestinal tract. We evaluated the gastrointestinal safety and anti‐inflammatory efficacy of a novel hydrogen sulphide‐releasing derivative of naproxen, ATB‐346 [2‐(6‐methoxy‐napthalen‐2‐yl)‐propionic acid 4‐thiocarbamoyl‐phenyl ester].Experimental approach: The ability of ATB‐346 versus naproxen to cause gastric damage was evaluated in healthy rats and in rats with compromised gastric mucosal defence. Effects on the small intestine and on the healing of ulcers were also assessed. The ability of ATB‐346 to inhibit cyclooxygenase‐1 and 2 and to reduce inflammation in vivo was also evaluated.Key results: ATB‐346 suppressed gastric prostaglandin E2 synthesis as effectively as naproxen, but produced negligible damage in the stomach and intestine. In situations in which the gastric mucosa was rendered significantly more susceptible to naproxen‐induced damage (e.g. ablation of sensory afferent nerves, inhibition of endogenous nitric oxide or hydrogen sulphide synthesis, co‐administration with aspirin, antagonism of KIR6.x channels), ATB‐346 did not cause significant damage. Unlike naproxen and celecoxib, ATB‐346 accelerated healing of pre‐existing gastric ulcers. In a mouse airpouch model, ATB‐346 suppressed cyclooxygenase‐2 activity and inhibited leukocyte infiltration more effectively than naproxen. ATB‐346 was as effective as naproxen in adjuvant‐induced arthritis in rats, with a more rapid onset of activity. Unlike naproxen, ATB‐346 did not elevate blood pressure in hypertensive rats.Conclusions and implications: ATB‐346 exhibits anti‐inflammatory properties similar to naproxen, but with substantially reduced gastrointestinal toxicity.
- 1 August 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (2) , 569-578.e1
Endogenous and Exogenous Hydrogen Sulfide Promotes Resolution of Colitis in Rats
- 1 August 2009
- Published by Elsevier in Gastroenterology
- Vol. 137 (2) , 569-578.e1
Endogenous and Exogenous Hydrogen Sulfide Promotes Resolution of Colitis in Rats